Palmitoylethanolamide (PEA)
Also called: PEA, palmidrol
Palmitoylethanolamide is a naturally occurring fatty acid amide made in the body, described as an endocannabinoid-like bioactive lipid mediator. It is sold as a supplement, including micronized, ultramicronized and cold-water dispersible forms studied in trials.
- Category
- Other
- Forms
- Palmitoylethanolamide (PEA), including micronized, ultramicronized and cold-water dispersible formulations
- Strongest evidence
- B Some positive trials
- Reviewed
- 2026-10-30
Class 1 Well studied in people. A 2024 systematic review tabulates 47 RCTs (48 reports) in patient populations: at least 28 RCTs tested PEA alone (oral or sublingual; one topical cream), sometimes added to usual care, and 19 combined PEA with luteolin, polydatin or other compounds. [3]
Fact-checked 2026-10-30 · How this guide is made
Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.
What research has studied
Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.
BSeveral areas, whole body or blood2 topics
CBrain, mood and sleep1 topic
A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials
| Topic studied | Grade | What the evidence shows |
|---|---|---|
| Chronic pain | B | A 2023 meta-analysis of 11 double-blind RCTs (774 patients; 4 tested PEA with transpolydatin) found lower pain scores than comparators (SMD 1.68); no major side effects were attributed to PEA. [1] |
| Acute or chronic pain versus inactive control | B | A 2017 meta-analysis pooled 8 RCTs with inactive controls and found greater pain reduction with PEA; the authors note few trials, varied conditions and often poor study quality. [2] |
| Diabetic neuropathic pain | C | A 2026 meta-analysis of 3 studies (188 patients) found lower pain scores, but heterogeneity was high and combination formulations obscured PEA's own effect. [4] |
| Intraocular pressure in glaucoma or ocular hypertension | C | A systematic review included 6 studies (199 patients) and pooled 3; PEA reduced intraocular pressure. [5] |
Main constituents: Palmitoylethanolamide, an endogenous fatty acid amide [5]
Safety and side effects
- Liver (NIH LiverTox)Nothing found
No published information found in the sources checked.
Details and sources - Pregnancy and breastfeedingNothing found
No published information found in the sources checked.
Details and sources - Interactions with medicinesNothing found
No published information found in the sources checked.
Details and sources - Cancer evaluations (IARC, NTP)None found
No IARC or NTP evaluation was found in the lists checked.
Details and sources - FDA new dietary ingredient notifications2 on FDA's list
FDA does not approve dietary supplements. Each entry is one party's filing.
Details and sources - Dose in official monographsNone found
No published information found in the sources checked.
Details and sources
- In a 2023 meta-analysis of 11 double-blind RCTs, no major side effects were attributed to PEA in any study. [1]
- A 2017 meta-analysis describes PEA as generally well tolerated in research populations but notes that assessment of side effects in the underlying studies was often poor. [2]
- In diabetic neuropathic pain studies, safety data were limited; only mild, self-limited adverse events were reported. [4]
Identity, quality and standardization
- A 2024 systematic review found the strongest evidence for pain and general wellbeing with ultramicronized/micronized or cold-water dispersible formulations. [3]
Regulatory status
- US: under DSHEA, FDA does not have the authority to approve dietary supplements before they are marketed; firms are responsible for ensuring their products are not adulterated or misbranded. [6]
Safety, quality and supply profile
Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-30). If our sources do not answer a question, we say so.
Compounds responsible
Compounds the sources name as the main or characteristic actives.
- Palmitoylethanolamide (PEA), an endogenous fatty acid amide Fatty acids and lipids (fatty acid amide) [P1]
US status
What FDA's published records show. FDA does not approve dietary supplements.
- FDA's published NDI notification list has 2 entries naming palmitoylethanolamide (earliest NDI 820 submitted 2014-01-24; most recent NDI 867 submitted 2015-03-20). Each notification covers one firm's specific ingredient and conditions of use; the list does not state FDA's response. [P2]
Cancer evaluations (IARC and NTP)
Evaluations name the exact material tested, which may differ from a supplement.
- No IARC or NTP carcinogenicity evaluation of palmitoylethanolamide was found (IARC Monographs list of classifications, Volumes 1–142, and NTP technical reports checked 2026-10-30). [P3]
- The NTP Technical Reports index (TR-001 to TR-606) lists no study of palmitoylethanolamide (checked 2026-10-30). [P4]
Liver (NIH LiverTox)
- No published information found in the sources checked.
Interactions with medicines
- No published information found in the sources checked.
Alcohol
- No published information found in the sources checked.
Interactions with other herbs and supplements
- No published information found in the sources checked.
Adulteration and substitution
- No published information found in the sources checked.
What a certificate of analysis should cover
Tests a quality specification for this material would include, with the reason for each.
- Identity: at least one appropriate test or examination to verify the identity of each component that is a dietary ingredient (21 CFR 111.75(a)(1)(i)) — General Part 111 requirement for every dietary ingredient; FDA may exempt a firm only by granting a petition under 111.75(a)(1)(ii). [P5]
Supply and conservation
- No published information found in the sources checked.
Absorption in people
- No published information found in the sources checked.
Formulations studied to change absorption
Human data only.
- No published information found in the sources checked.
Dose in official monographs
As the monograph states it, for its jurisdiction; not personal advice.
- No published information found in the sources checked.
Pregnancy and breastfeeding
- No published information found in the sources checked.
Sources for this profile
- Crupi L, et al. Evaluation of the nutraceutical Palmitoylethanolamide in reducing intraocular pressure (IOP) in patients with glaucoma or ocular hypertension: a systematic review and meta-analysis. Nat Prod Res 2025;39(4):797-816 (PMID 38269580), 2024-01-25. pubmed.ncbi.nlm.nih.gov
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- IARC Monographs. List of Classifications: agents classified by the IARC Monographs, Volumes 1–142, 2026-10-30. monographs.iarc.who.int
- National Toxicology Program. Technical Reports (TR series index, TR-001 to TR-606), 2026-10-30. ntp.niehs.nih.gov
- eCFR. 21 CFR 111.75, What must you do to determine whether specifications are met? (up to date as of 10/29/2026), 2026-10-29. ecfr.gov
Sources
- Lang-Illievich K, et al. Palmitoylethanolamide in the Treatment of Chronic Pain: A Systematic Review and Meta-Analysis of Double-Blind Randomized Controlled Trials. Nutrients 2023;15(6):1350 (PMID 36986081), 2023-03-10. pubmed.ncbi.nlm.nih.gov
- Artukoglu BB, et al. Efficacy of Palmitoylethanolamide for Pain: A Meta-Analysis. Pain Physician 2017;20(5):353-362 (PMID 28727699), 2017-07. pubmed.ncbi.nlm.nih.gov
- Bortoletto R, et al. Palmitoylethanolamide supplementation for human health: A state-of-the-art systematic review of Randomized Controlled Trials in patient populations. Brain Behav Immun Health 2025;43:100927 (PMID 39839988), 2024-12-23. pubmed.ncbi.nlm.nih.gov
- Prado MB Jr, et al. Efficacy, safety, and tolerability of palmitoylethanolamide in the management of diabetic neuropathic pain: a systematic review and meta-analysis. J Diabetes Metab Disord 2026;25(1):52 (PMID 41664677), 2026-02-07. pubmed.ncbi.nlm.nih.gov
- Crupi L, et al. Evaluation of the nutraceutical Palmitoylethanolamide in reducing intraocular pressure (IOP) in patients with glaucoma or ocular hypertension: a systematic review and meta-analysis. Nat Prod Res 2025;39(4):797-816 (PMID 38269580), 2024-01-25. pubmed.ncbi.nlm.nih.gov
- U.S. Food and Drug Administration. Questions and Answers on Dietary Supplements (content current as of 08/27/2026), 2026-08-27. fda.gov
- A
- Consistent results from several randomized trials or a systematic review of them
- B
- Some positive randomized trials, but small, short, few or inconsistent
- C
- Limited human evidence: single small trials, observational data or mixed results
- D
- Laboratory or animal evidence only; not shown in people
- X
- Well-designed human trials found no meaningful effect
More in this category: Alpha-lipoic acid · Bee pollen · Beetroot juice (dietary nitrate) · Berberine · Beta-glucan (oat and barley) · Betaine (trimethylglycine) · Bromelain · Caffeine · All entries A–Z · How to judge a supplement
Health information notice
These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.
Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.